Our study showed that the low-risk group had higher IPS, IPS-PD-11/PD-L1/PD-L2, and IPS-CTLA4 scores, suggesting that HCC patients in the low-risk group might have a better response to anti-CTLA-4 and anti-PD-1 antibodies. Here, CTLA4 is linked to hepatocellular carcinoma.